Dr. Kung is a founding member and partner of Vivo Capital. Dr. Kung started his career in the biotech industry in 1979 when he joined Cetus Corporation. He co-founded Cetus Immune Corporation in 1981, which was acquired by its parent company Cetus in 1983. In the same year he co-founded Genelabs Technologies, Inc. where he served as the Chairman and CEO until 1995. During his tenure at Genelabs, he brought the company public in 1991 (NASDAQ: GNLB) and built it to a 175 employee international biotech company with operations in the United States, Belgium, Singapore, Switzerland, and Taiwan.

Dr. Kung received his B.S. in chemistry from the National Tsing Hua University in Taiwan and his Ph.D. in molecular biology and M.B.A. from the University of California, Berkeley. He received the Best Use of Technology Award from the Governor of California as well as Entrepreneur of the Year Awards from Ernst and Young and the Asian Business League. He also served on the board of directors for the Emerging Company Governing Body of the Biotechnology Industry Organization (BIO), Mt. Jade Science and Technology Association (West Coast), and the Asian American Manufacturing Association. He was appointed by the U.S. Secretary of Health and Human Services as a voting member of the National Biotechnology Policy Board.

Edgar Engleman, M.D. is a founding member and Chief Scientific Advisor of Vivo Capital. Dr. Engleman is a Professor of Pathology and Medicine at Stanford University School of Medicine, where he established and oversees the Stanford Blood Center, directs his immunology research team, and co-directs the Tumor Immunotherapy Program of the Stanford Cancer Institute. He is an inventor of multiple patented technologies, has authored more than 350 publications in medical and scientific journals, and trained more than 100 graduate and postgraduate students. Dr. Engleman is the lead inventor of the technology underlying a cancer immunotherapy known as Provenge (Sipulucel-T), which was shown to extend the life of patients who suffer from metastatic prostate cancer. Provenge is the first in the class of personalized immunotherapeutic agents to be FDA approved for the treatment of cancer. He is also the lead inventor of the technology underlying the immunotherapies in development at Bolt Biotherapeutics.

Dr. Engleman is the founder or cofounder of a number of biotech companies including Cetus Immune (acquired by Novartis), Genelabs (acquired by GlaxoSmithKline), Dendreon (acquired by Sanpower) and Bolt. He currently serves on the boards of Bolt (BOLT) and several private companies. He previously served on the boards of Soleno (SLNO), REGENEXBIO (RGNX), Eiger (EIGR), Intermune (ITMN, acquired by Roche), Insmed (INSM), Prestwick (acquired by Biovail) and Semnur (acquired by Sorrento (SRNE).

He received his BA from Harvard College and earned his M.D. from Columbia University School of Medicine. In 2017, he received the CABS K Fong Prize for achievements in life sciences, and in 2022, he received the Columbia University Gold Medical for Outstanding Achievement in Medical Research.

Shan Fu joined Vivo in 2013 as a Managing Partner, Co-CEO, and CEO of Asia Pacific. Before joining Vivo, Mr. Fu worked for Blackstone as Senior Managing Director in the Private Equity group and the Chief Representative of Blackstone’s Beijing Office. Mr. Fu also worked in the Department of Foreign Investment in China’s National Development and Reform Commission (NDRC), the State Economic and Trade Commission of China, the Office of Economic and Trade in State Council of China, and the Office of Production in State Council of China.

Mr. Fu serves on the boards of a number of public and private healthcare companies. Currently, he serves as Chairman of the Board at TOT Biopharm (SEHK:1875) and Evaheart. He also serves on the boards of Sinovac Biotech, Lepu Scientech (SEHK:2291), Caidya, New Frontier Health, Esco Lifesciences Group and Visen Pharmaceuticals.

Mr. Fu received a Bachelor’s and Master’s Degree in History from Peking University in Beijing, China.

Dr. Aggarwal has been an investor in the life sciences sector for more than twenty years. He rejoined Vivo as a Managing Partner in April 2024 after being a Managing Director from 2016 to 2023 and Chief Investment Officer for the U.S. public investment fund from 2021 to 2023. Dr. Aggarwal previously served as the Chief Business Officer of Ocera Therapeutics, Inc., a publicly traded clinical stage company developing therapies for orphan liver conditions, from April 2014 through October 2016, and as Managing Director of Investor Growth Capital from January 2013 through December 2013. Additionally, he was a General Partner at Panorama Capital, L.P., a venture capital fund, from August 2006 through December 2012. Earlier in his career, Dr. Aggarwal was an associate with JPMorgan Partners, LLC, a private equity division of JPMorgan Chase & Co.

Dr. Aggarwal has served on the boards of Unicycive Therapeutics and Geron since March 2023 and November 2023, respectively. He previously held positions on the boards of Sierra Oncology, Inc. (acquired by GlaxoSmithKline plc), Hyperion Therapeutics, Inc. (acquired by Horizon Pharma plc), and on several privately held biopharmaceutical companies.

Dr. Aggarwal received his M.D. from Columbia University, College of Physicians & Surgeons and his B.S. in Agricultural Economics from Cornell University.

Michael Chang, M.B.A., is a Managing Partner of Vivo Capital. He joined Vivo with a background in healthcare strategy and operations. Prior to Vivo, he worked at Johnson & Johnson in the strategy and commercial planning function, and as a strategy consultant at both Booz & Company and Fletcher Spaght.

Michael graduated with a bachelor’s degree in Economics from Harvard College and an M.B.A. from Harvard Business School.

Michael Chan, Ph.D., is an Analyst at Vivo Capital with a background in biomedical engineering research and technology commercialization. Prior to joining Vivo, Dr. Chan served as a Part-time Fellow at Columbia Technology Ventures (CTV) and as a Graduate Researcher at Columbia University, where he presented projects with NASA and published work on bone regenerative materials. He also assisted in seed capital funding for a COVID-19 therapeutic through the BioMedX Accelerator Program. Dr. Chan earned his Ph.D in Biomedical Engineering from Columbia University.  He also holds a bachelor’s degree from the University of Bath and M.S degree from University College London.

Albert joined Vivo Capital in 2017 and is a member of the investment team.

Albert has more than 23 years of institutional investment experience, including the past 15 years specializing in small- and mid-cap biotechnology and pharmaceutical companies. His expertise spans market structure, liquidity, portfolio implementation, and risk management, developed through multiple market cycles.

At Vivo Capital, Albert oversees the firm’s public equity trading strategy and execution, partnering with portfolio managers to implement investment decisions. He uses market analysis, trading technology, and a network of institutional counterparties to support the firm’s investment objectives.

Prior to joining Vivo Capital, Albert was Head Trader at Palo Alto Investors. Earlier in his career, he traded across a diverse range of sectors, including technology, energy, financial services, consumer, and medical technology, providing him with a broad perspective on global equity markets.

Albert earned a B.A. in Biology from Harvard University.

Kevin Dai, Pharm.D, BCOP, joined Vivo with healthcare and sell side equity research experience. Prior to Vivo, Kevin worked at Memorial Sloan Kettering Cancer Center for 3 years as a Clinical Oncology Pharmacy Specialist in the hematology department, where he provided direct patient care and managed all active clinical trials within the leukemia department. He then worked at Canaccord Genuity as an equity research associate covering small to large cap biotechnology and specialty pharmaceutical companies. Additionally, Kevin interned at Merck & Co. in the ion channel department, where his research has been published in multiple medical journals, including Biochemistry, PNAS, and Bone Marrow Transplantation.

Kevin received a Pharm.D from Ernest Mario School of Pharmacy at Rutgers. He then completed his internal medicine residency at University of Chicago Medical Center, and his oncology residency at Memorial Sloan Kettering Cancer center. He is a board certified oncology pharmacist (BCOP).

Richard Ding is an Analyst at Vivo Capital. Prior to joining Vivo, he worked at Shine Asset Management, focusing on investments in biopharmaceuticals and computational biology.

Richard holds an master’s degree in financial engineering from Cornell University and a bachelor’s degree in computer science and engineering from The Chinese University of Hong Kong. He was also a visiting scholar at the University of California, Berkeley, conducting research in artificial intelligence.

Hao Dong is a Managing Director at Vivo Capital and has over 12 years of experience in investment and entrepreneurship. Prior to joining Vivo Capital, Hao worked at Qianhai Ark Asset Management, China’s largest fund of funds (FOF), and he also previously co-founded a technology start-up that successfully completed a NASDAQ IPO. Early in his career, he worked in the investment banking department at Morgan Stanley and Deutsche Bank.

Hao received a B.S. in financial engineering from the University of International Business and Economics.

Minjun Feng is a Principal at Vivo Capital, focusing on life science investments and company formation. Prior to Vivo, Minjun worked at RTW Investments and Corxel Pharmaceuticals, contributing to asset evaluation, company incubation and clinical development. Previously, Minjun coordinated clinical trials at the Medical University of South Carolina.

Minjun holds an M.A. in Biotechnology from Columbia University and a B.A. in Biology from Franklin & Marshall College.

Andrew Huang, is a Principal of Vivo Capital. Mr. Huang is responsible for executing growth and private equity investments.

Prior to joining Vivo, Andrew worked at Audax Private Equity, where he focused on investments in healthcare and business service companies. Earlier in his career, he was an investment banker at J.P. Morgan, where he focused on mergers and acquisitions for technology and healthcare clients.

Andrew graduated from the University of California at Berkeley with a B.A. in Economics.

Jessica Li, is an Associate at Vivo Capital.  She joined Vivo with a quantitative background.  Her most recent experiences include working in the asset management division of CITIC Trust Co., with the audit group at Shinewing International, and with The International Trade Administration of the US Department of Commerce in New York.

She received her B.A. in Economics from New York University and her M.S. in Business Analytics with a concentration in Finance from Duke University’s Fuqua School of Business.

Xiaoyang Li, Ph.D., joined Vivo with a multidisciplinary research background focusing on medical sciences, nanotechnology, and chemistry. Xiaoyang graduated with First Class Honors from Imperial College London with a B.Eng. (Bachelor of Engineering) in Materials Sciences and Engineering. She received her Ph.D. in Chemistry from Stanford University.

Her research findings were published in leading peer-reviewed journals such as Small, JCM and PNAS. Xiaoyang also completed research in the National Laboratories at Tsinghua University, Chinese Academy of Sciences, and clinical research at the Peking University People’s Hospital. Xiaoyang also completed internships with Blackstone Group as an analyst and at Cisco and FedEx with the strategic consulting team.

Yixuan Li joined Vivo in 2017 with a quantitative background. Prior to Vivo, Yixuan worked as a public investment private equity associate at Beijing Automotive Industry Holdings, focusing on M&A, reverse mergers and market expansion in the healthcare sector. She led and executed investments in nine listed companies.

Yixuan received an M.S. in Mathematical Modeling and Scientific Computing from University of Oxford and a B.S. in Mathematics with Finance from University of Liverpool. She also obtained a FRM certificate in 2012.

David Liu, Ph.D., is a Partner at Vivo Capital.He joined the firm with over 15 years of experience in Process R&D and CMC management in the pharmaceutical industry. He has led the development and implementation of novel and efficient chemical processes for tens of programs ranging from pre-IND to late stage Phase III. Prior to Vivo, he worked at STA-WuXi Apptec as Executive Director of Process Research & Development. Prior to STA, he was Director of Process Chemistry with Avista Pharma Solutions and Principal Research Investigator with Array BioPharma.

David received his B.S. and M.S. in Chemistry from Peking University and Ph.D. in Organic Chemistry from University of Pittsburgh. He completed his postdoctoral research at Texas A & M University.

Jiawei Liu is a Principal at Vivo Capital. He joins the firm with consulting and clinical experience. Prior to joining Vivo Capital, Mr. Liu worked at Boston Consulting Group as a management consultant in the healthcare industry, helping multinational and local biopharma companies on various topics including R&D strategy, regulation & policy shaping, and launch excellence & pricing. He also served private equity clients on commercial due diligence projects.

Mr. Liu holds a medical degree from Shanghai Jiao Tong University and completed the doctor trainee program at Shanghai General Hospital.

Darren Long is a Senior Associate – PIM at Vivo Capital. He joins the firm with a background in healthcare strategy consulting, business development, and commercial operation. Prior to Vivo, Darren was with BeiGene’s Business Strategy group, focusing on internal clinical pipeline strategy and external business development/collaboration. Before BeiGene, he served as a consultant at IQVIA Singapore, focusing on the Southeast Asia pharmaceutical sector. He also served Shimadzu in its analytical instrument APAC commercial operations and MSD in its analytical chemistry department.

Darren graduated with a bachelor’s degree in Chemistry and Biological Chemistry from Nanyang Technological University Singapore and an M.B.A. from INSEAD France/Singapore.

Mike Lu, Ph.D., is a Principal at Vivo Capital. Dr. Lu joined Vivo with a background in sell side research and benchtop chemical biology research. Prior to joining Vivo, Dr. Lu worked as a healthcare equity research analyst with a focus on biotech and medtech at Goldman Sachs.

Dr. Lu received his B.A. in Chemistry from Wabash College and a Ph.D. in Chemistry from Massachusetts Institute of Technology. His Ph.D. work was primarily focused on drug delivery and protein engineering.

Zhongyi Lu joined Vivo with a background in private equity and investment banking. Prior to joining Vivo, he worked in private equity at EQT and CITIC Xinjin starting in 2015, focusing on cross-border buy-out investments and portfolio management in healthcare and consumer sectors. Before private equity, he worked in investment banking at Nomura, HSBC, and CEC Capital.

Zhongyi received a B.S. in Chemistry from the California Institute of Technology, M.S. in Biotechnology from the Johns Hopkins University, and MBA from the Wharton School of the University of Pennsylvania. He was a trainee at the Medical Scientist Training Program of the University of Washington School of Medicine before his career in investment banking and private equity.

Chen Meng, Ph.D., is a Managing Director at Vivo Capital. Dr. Meng has over 20+ years of experience in private equity and healthcare investment. Prior to joining Vivo, Dr. Meng served as Managing Director at New Frontier Group, a premium healthcare services group, where he was responsible for portfolio investments and operations management. Before that, he worked for one of Asia’s largest sovereign funds, where he specialized in alternative asset allocation and headed the fund’s global healthcare strategy.  Dr. Meng holds a Ph.D. in International Business from the University of Leeds, UK.  

Gilles Nkana is a Principal at Vivo Capital. Prior to Vivo, Gilles was an investor at Alta Semper Capital, a London-based private equity fund focused on healthcare buyouts and growth equity investments. Prior to joining Alta Semper, Gilles worked at Goldman Sachs in the Investment Banking Division where he focused on M&A and financing transactions for Industrial and Technology, Media and Telecom (TMT) clients.

Gilles graduated from Columbia Business School with an M.B.A. He also obtained a Master of Science from EM Lyon (France) and Ludwig Maximilian University of Munich (Germany) with a specialization in Corporate Finance.

Timothy Stubbs, M.D., B.Sc. is an Executive Director at Vivo Capital. Prior to Vivo, he was a Vice President at Morgan Stanley, where he worked in the Healthcare Investment Banking team for more than 7 years, in both London and San Francisco. At Morgan Stanley, he covered clients across multiple healthcare subsectors including large cap pharma, biotechnology, medical technology, diagnostics, and digital health. Dr. Stubbs has worked on a large number of high profile and cross-border M&A and equity transactions, including acquisitions, co-development and co-commercialization agreements, and IPOs, among others. Prior to Morgan Stanley, he worked as an NHS physician in London, where he spent time in medical and surgical specialties, as well as the ER.

Dr. Stubbs received his medical degree and bachelors of science in Anatomical Science (first class honors) from the University of Bristol, UK. During his medical career he also worked in research roles, contributing to clinical trials including the randomized Multicenter Uveitis Steroid Treatment (MUST) trial. He has presented and published work in various subspecialties, including vascular disease, ophthalmology, and orthopedics.

Linus Tan, Ph.D., joined Vivo with a fundamental and translational research background in the biomedical field. Prior to Vivo, Linus worked for China Asset Management Co., Ltd. as a senior associate focusing on Biotech, Vaccine, and CRO industries. He also served as a research assistant for Novo Nordisk A/S in discovery and optimization of next-generation peptide drug candidates.

Linus has conducted research in peptide drug discovery and ubiquitin signaling pathway and published his research in multiple peer-reviewed journals, including JACS, ChemComm, and CCL. Linus received his B.S. in Organic Chemistry from University of Science & Technology of China and Ph.D. in Chemical Biology from Tsinghua University.

Jing Wang is a Senior Associate at Vivo Capital. Prior to Vivo, she worked at Investcorp, a Middle East headquartered alternative investment manager and focused on its control buyout business in the Greater China. Earlier in her career, she worked at one of Asia’s largest sovereign funds, covering growth and buyout transactions in the healthcare space.

Ms. Wang graduated with a Master’s degree in Finance from the University of Hong Kong and a Bachelor’s degree in Economics from Tsinghua University.

Zhao Wei joined Vivo with private equity and investment banking background. Prior to Vivo, he worked at VMS Group and CDH Investments, focusing on private equity investments in healthcare sector. Earlier in his career, he worked in the investment banking division at BNP Paribas.

Zhao received an MBA from Columbia University and a Bachelor’s Degree in Engineering from The University of Hong Kong.

Daisy Xu joins Vivo with a wealth of experience in commercial operations, focused on the life science and medical equipment industries. Prior to joining Vivo, Daisy was Commercial Leader at ThermoFisher China, where she was responsible for overall management of commercial operations and helped to establish the company’s business model. Prior to ThermoFisher, she was General Manager of Kinetic Concept Inc. Greater China and the head of Bio-Rad’s Greater China operations. Daisy graduated from East China University of Science and Technology with an M.S. in Bio-engineering and a B.S. in Pharmaceutics.

Allison Yan joined Vivo with a financial advisory and auditing background. Prior to Vivo, Allison worked at Ernst & Young in its financial accounting advisory service and audit practices. Allison has a wealth of experience in IPO auditing, acquisition and restructuring transaction advisory, operation optimization, and SOX 404 internal control compliance and accounting standards implementation.

Allison received an M.A. in Accounting from North Carolina State University and a B.A. in Accounting from Zhejiang University. She is a US Certified Public Accountant.

Pierre You is a Principal, PIM at Vivo Capital. He joined the firm with a background in audit and private markets investment. Prior to Vivo, Pierre worked at Deloitte in auditing and focused on private markets investment at Fosun Group and OFC Capital, where he accumulated experience in risk control, due diligence, and post investment management.

Pierre received an M.B.A. from CEIBS and a B.A. in French Literature from Shanghai International Studies University.

Kate Zhang, M.S., is a Senior Associate at Vivo Capital. She joined Vivo with an investment banking background. Prior to Vivo, Yue worked at CEC capital and Index Capital, focusing on healthcare service and technology.

Ms. Zhang received her M.S. in Finance from Renmin University of China and her B.S. in Financial Mathematics from Central University of Finance and Economics.

Sean Zhang, Ph.D. is an Executive Director at Vivo Capital. Prior to Vivo, he was a Vice President at Lilly Asia Ventures, where he focused on biotech venture capital investments and new company incubation. Prior to that, Sean was a management consultant at McKinsey & Company and provided strategic consulting to pharmaceutical and biotech companies on areas such as R&D strategy, sales & marketing, and due diligence. He also has hands-on experience working at biotech companies such as Ocelot Bio and Allele Biotech. Sean currently serves as a member of the Board of Directors of Rgenta Therapeutics and board observer at Zenas Biopharma. He previously served on the board of directors of ADARx Pharmaceuticals, Perfuse Therapeutics, and Proteologix.

Sean received his Ph.D. in Molecular Biology at University of Pittsburgh School of Medicine and B.E. of bioengineering at Xi’an Jiaotong University. Additionally, he completed his postdoctoral training at the University of California San Diego.

Zoe Zhang, Ph.D., joined Vivo with investment banking and R&D experience. Prior to Vivo, she worked at CEC Capital with a focus on the biotechnology and pharmaceuticals sectors. Earlier in her career, she worked at Genecast as a senior researcher.

Dr. Zhang received a Ph.D. in Bioengineering from the Hong Kong University of Science and Technology, an M.S. in Nanoscience and Nanotechnology from KU Leuven, and a B.S. in Biomedical Engineering from Southeast University. She was a visiting scholar at Rice University.

Lingfei Zhao joined Vivo with a quantitative background. She completed her B.S. in Economics and Mathematics and M.S. in Statistics from University of Wisconsin-Madison and Cornell University, respectively. During her undergraduate and graduate years, she did an internship with BNP Paribas with the fixed income research team and a summer internship at Blackstone Group as a private equity analyst.

Wenping Zhou, Ph.D., is an Associate at Vivo Capital. She brings a background in biotech venture capital and sell-side equity research. Prior to joining Vivo, Dr. Zhou contributed to SMID biotech equity research at Cantor Fitzgerald and Evercore ISI. Earlier, she served as a biotech investment associate at Connecticut Innovations.

Dr. Zhou earned her Ph.D. in Cell Biology from Yale University. She also holds a bachelor’s degree in biology from Nanjing University.

Cinthia Sheu, M.B.A., is the Partner and COO of Vivo Capital, overseeing administrative, finance, information technology, and tax of the firm. She works closely with the legal team on fundraising, operations, and regulatory compliance matters.

Cinthia has over 25 years of professional experience in financial services and has been working in the private equity industry since 1999. Prior to joining Vivo, she was the controller at Infinity Capital, a technology venture capital firm. She began her professional career in public accounting as a tax manager with PwC, serving various private and public clients in the financial and technology sectors.

Cinthia holds a B.A. in Economics from National Taiwan University and her M.B.A. from University of Texas at Dallas. She is a Certified Public Accountant, CPA, in California.

Zhanping Wu, J.D., is a partner, general counsel, and chief compliance officer for Vivo Capital.  Zhanping oversees the firm’s legal, compliance, and regulatory programs and also advises on fund formation, deal structuring and execution, post-investment management, and portfolio exits.

Prior to joining Vivo Capital, Zhanping held the role of director and corporate counsel at FibroGen, Inc. (FGEN), a public biopharmaceutical company. Previously, she was an attorney in the Palo Alto office of Perkins Coie LLP, advising emerging and growth technology companies in formation, venture capital financings, M&A, public offerings, and technology transfer transactions.

Zhanping received her B.A. in philosophy and completed her M.A in law from Peking University. She earned her J.D. from the University of California, Davis School of Law and is a member of the State Bar of California.

Vivian Chiau is a Senior Vice President of Finance at Vivo Capital.  Vivian joined Vivo in 2005 and is responsible for all aspects of accounting operations, overseeing all transactions related to financials reporting, handling financials requests from LPs, and working with outside auditors. 

Vivian has extensive experience in the financial industry. She has over 20 years of experience in the venture capital industry.  She has worked previously at CDIB Venture Management, Inc., a Santa Clara-based private venture capital firm focused on technology. Before entering the VC industry, Vivian worked in a commercial bank in Taiwan and was an auditor in an accounting firm.

Vivian received her B. A. in Accounting from National Taiwan University and an M.B.A. from National Cheng-chi University in Taiwan. 

Nina Feng joined Vivo in 2016 as a Principal in the Taipei office. Before joining Vivo Capital, Nina worked at Cathay Life Insurance Company, a subsidiary of Cathay Financial Holding Company, the largest financial group in Taiwan. Nina was responsible for private equity investments, managing more than USD2 billion across growth capital, venture capital, and healthcare strategies. She has more than 8 years of experience in alternative investments and extensive experience in hedge fund investments. Alongside with the Financial Group expansion plan in ASEAN, Nina was part of the team responsible for the equity acquisition in ASEAN banks.

Nina Feng received a Bachelor’s degree in Finance and an M.B.A. from National Cheng-Chi University. She received the Phi Tau Phi Scholastic Honor and obtained a CFA certificate in 2006.

Jane Gong is a Principal on Vivo Capital’s Investor Relations team. Having joined the firm in 2021, she works closely with the investment, finance, and legal teams on fundraising activities, investor coverage and reporting, and stakeholder communications.

Prior to joining Vivo, Jane was on the Investor Relations team of New Horizon, Advantech, and Redview Capital platform, where she engaged in executing the IR program and supporting post-investment management activities. Previously, Jane was an Investment Banking Analyst at Houlihan Lokey (NYSE:HLI), where she specialized in cross-border mergers and acquisitions, as well as take-private transactions. Early in her career, she also worked for a financial advisory firm focused on raising capital for Israeli start-ups in the high-tech and healthcare sectors.

Jane received her bachelor’s degree in Honors Business Administration from the Richard Ivey School of Business at the University of Western Ontario in Canada.

Wei Li is an Analyst, IR at Vivo Capital. She joins the firm with an advisory, auditing and finance background. Prior to Vivo, she worked at Ernst & Young in Financial Accounting Advisory Services. Before Ernst & Young, she served as Financial BP in ByteDance and Kuaishou.

Wei received an M.A. in Finance from the University of International Business and Economics and a B.A. in Finance from Jilin University.

Sophia Sun is the Vice President, Head of China Operations at Vivo Capital. Sophia joined Vivo in 2013 and is responsible for overseeing operational matters in the Greater China offices.  Sophia has over 25 years of operational management experience in multinational companies. Prior to joining Vivo, she worked at Servier, Monitor Group (acquired by Deloitte), McKinsey & Company, and Bayer.

Sophia received her B.A. in English Literature from the University of International Relations and her M.S. in International Business from the University of Nottingham, England.

Brad is an Associate, IR at Vivo Capital, where he supports the firm’s investor relations and fundraising initiatives. Prior to joining Vivo, Brad was an Associate at Horsley Bridge Partners, where he focused on investor relations, capital raising, and secondary transactions. He started his career in Hong Kong as an Investment Banking Analyst in Eaton Partners’ Private Funds Group.

Brad holds a B.A. in Political Economy from New York University.

Vera Yang is a Senior Associate, IR at Vivo Capital. She joins the firm with an advisory and auditing background. Prior to Vivo, Vera worked at Ernst & Young in its advisory service and audit practices. Vera has a wealth of experience in SPAC audit, internal control optimization, and accounting standards implementation.

Vera received an M.A. in Accounting from the University of Illinois at Urbana-Champaign and a B.A. in Finance Management from China Youth University of Political Studies. Vera is a US Certified Public Accountant and also has a Legal Professional Qualification Certificate of China.

Chole Zhang is a Principal at Vivo Capital, focused on sustainability initiatives. Before joining VIVO, Chloe worked at China Orient Asset Management International Limited (“COAMI”) as Director in Leveraged Finance Team. COAMI is a subsidiary of COAM which is one of the big four state-owned asset management institutions in China. Chloe managed a portfolio with highest AUM of HK$ 4.5 Billion with investments across mezzanine debt, share-pledged financing, privatization, cross border M&A and pre-IPO. Chloe also established a private equity fund with AUM of US$ 300 Million and acted as the Board of Director of the GP company. Chloe also worked at the Bank of China Group Investment Limited and Ernst & Young New York Office before.

Chloe is a Responsible Officer of Type 4&9 license from HK Securities and Futures Commission. She holds a B.B.A in Finance and M.S in Accounting from New York.

Julie Zhang is a Vice President of Tax.  Julie oversees tax function at Vivo Capital, including global tax compliance and transaction support.  Julie has over 20 years of tax advisory and management experience in the PE/VC industry, with broad technical knowledge on key jurisdiction tax regimes, mergers and acquisitions, and cross-border investment transactions related tax issues.

Prior to joining Vivo Capital, Julie worked as an International and M&A tax director in Deloitte China and a M&A tax manager in PwC US, where she advised US and China PE/VC funds on setup and inbound/outbound investment structuring.  She was the key author of the China tax industry edition of “Private Equity and Venture Capital Fund in China”, published by CCH and Deloitte’s publication of “China Mergers, Acquisitions and Reorganization Tax Guide”.

Julie received her B.S from Shanghai Jiaotong University and M.S in Accounting from Bentley University.

Christine Zhou is an Analyst on Vivo Capital’s Investor Relations team, where she focuses on client servicing, fundraising support, and cross-functional coordination across investment and operational teams. Prior to joining Vivo, she was a Research Associate in the Asia Pacific Diversified Industries group at J.P. Morgan’s Commercial and Investment Banking division, where she specialized in industry and company research and was actively involved in cross-border M&A and IPO transactions. Christine holds a Master of Science in Finance and Accounting from Imperial College London and a Bachelor of Arts in Accounting and Finance from Durham University. She is also a member of the Association of Chartered Certified Accountants (ACCA).

Qi Zhu is the Head of Talent and Organization Development at Vivo Capital. She oversees Vivo’s Human Resource matters and aligns the global talent strategies with the organization’s overall goals and objectives.

Qi joined Vivo in 2013 with a healthcare strategy background. She first joined as an investment professional before transferring to her current role as Head of Talent and Organization Development in 2020.

Prior to Vivo, Qi worked for McKinsey & Company, where she helped multinational pharmaceutical companies and large Chinese companies with corporate strategy, as well as organizational strategy.

Qi graduated from Fudan University management school with a B.A. and M.A. in Accounting.

Mike Preigh, Ph.D. has over 30 years of experience in pharmaceutical product development and manufacturing. Most recently (2019-2024), he was CTO at Day One Biopharmaceuticals leading the CMC development, NDA filing, and commercialization, for Ojemda (tovorafenib). Prior to joining Day One, he was an independent consultant supporting multiple venture backed start-up companies. From 2005-2015, Mike was at Array BioPharma where he led the CMC team that developed, manufactured, and filed INDs for 20+ new chemical entities including marketed drugs binimetinib (Mektovi) and tucatinib (Tukysa). He started his industry career at Pfizer where he spent 12 years in Manufacturing, Quality, and R&D. 

Dr.Mike received his Ph.D. in Chemistry from the University of Pittsburgh and his B.A. in Chemistry from Illinois Wesleyan University.

Mahendra G. Shah, Ph.D. is a highly successful pharmaceutical entrepreneur and executive.  After more than 15 years with Vivo Capital, he has transitioned into an Advisor role. Dr. Shah is the founder of Semnur Pharmaceuticals.  He is currently on the board of directors of Scientia Vascular and HCMed Innovations.  He was previously on the board of directors of several public companies, including Verona Pharma plc (NASDAQ: VRNA), Impel Neuro Pharma (NASDAQ: IMPL) , Soleno Therapeutic (NASDAQ: SLNO), Biotie Therapies (NASDAQ: BITI) and Bolt Therapeutics (NASDAQ: BOLT).  He was also on the board of directors of a number of privately held companies.  He was also a member of the board of trustees of St. John’s University and EPIC.

From September 2005 to December 2009, he was the founder, chairman, and CEO of NextWave Pharmaceuticals, a pediatric focused specialty pharmaceutical company, which was sold to Pfizer for a total of $700 million in upfront and milestone payments. From 1993 to May 2003, he was the chairman and CEO of First Horizon Pharmaceuticals, a publicly traded specialty pharmaceutical company, where he raised over $200 million and built a highly profitable company before it was sold to Shionogi Pharmaceuticals for $1.4 billion. From 1991 to October 1999, he was vice president of E. J. Financial Enterprises, Inc., which manages a fund that invests in healthcare companies. He previously served on the boards of Unimed Pharmaceuticals (UMED), Introgen Therapeutics (INGN), Inpharmakon, Protomed, Structural Bioinformatics, and Zarix.

From 1987 to 1991 he was the senior director of new business development with Fujisawa USA (Astellas). Prior to that time, he worked in various scientific and management positions with Schering-Plough and Bristol Myers-Squibb. Dr. Shah received his Ph.D. in industrial pharmacy from St. John’s University and his Bachelor’s and Master’s Degree in Pharmacy from L.M. College of Pharmacy in Gujarat, India.

Dr. Shen joined Vivo Capital in 2016 as a Venture Partner. She is an international pharmaceutical executive with more than 40 years of experience in the industry. Dr. Shen was the President and CEO, Board Member, and co-founder of ScinoPharm Taiwan, Ltd, a publicly listed leading process R&D and API manufacturing service provider to the global pharmaceutical industry.

Prior to establishing ScinoPharm in 1997, Dr. Shen was previously Corporate Vice President of Pharmaceutical Operations and Technology for Syntex from 1981, where she served for 14 years, responsible for worldwide pharmaceutical manufacturing, operations, and technology transfer.  Before that, she worked at Monsanto for 8 years in various technical and management positions in the synthetic fibers and semiconductor materials divisions.

Dr. Shen is a former board member of the U.S. Pharmaceutical Manufacturer Association (PhRMA), where she chaired the Production Group. She currently serves on a number of boards including the Development Center for Biotechnology, Taiwan Bio Industry Organization, China Chemical Society, and Taiwan Pharmaceutical Manufacturing Association (TPMA) where she chairs the Active Pharmaceutical Ingredients Committee.

Dr. Shen holds a Ph.D. in Chemistry from Lehigh University, an M.S. in Chemistry from University of Iowa and a B.S. of Chemical Engineering from National Taiwan University. Dr. Shen is the recipient of the “Women in Industry” award from the YWCA in California.

Dr. Tsay joined Vivo Capital in 2016 as a Venture Partner. He has extensive experience and a track record in building successful businesses that were eventually acquired or went public. Prior to his retirement in 2010 from Thermo Fisher Scientific (NYSE: TMO), Dr. Tsay served as Senior Vice President and Group President of the company’s Specialty Diagnostic business with a worldwide annual revenue of USD2 billion. He was the Group President of Immunodiagnostics of Fisher Scientific (NYSE: FSH) prior to Fisher’s merger with Thermo Electron in 2006. From 2000 to 2004, he served as Group President of Clinical Diagnostics of Apogent (NYSE: AOT), which was acquired by Fisher in 2004. While working for these public companies, he was instrumental in engineering the acquisition of multiple diagnostics companies including Phadia, One Lambda, BRAHMS, Microgenics, Seradyne, Duke Scientifics, and Applied Biotech Inc. He was the founder of Diagnostics Reagents Inc., which was acquired by Apogent in 1998. He also cofounded several other diagnostic companies, which were either acquired by a public company or went public.

Dr. Tsay serves on the boards of several biotech companies including PEG Bioscience, PharmaLegacy, AltheaDx, ReadCoor and Bonraybio. He also serves as a Scientific Advisor for Personal Genomics.

Dr. Tsay received his B.S. in Chemistry from the National Cheng Kung University in Taiwan. He has a Ph.D. degree in Organic Chemistry from the University of Rochester, New York. He received a Distinguished Scholar Award from the University of Rochester (2014) and the Distinguished Alumni Awards from Cheng Kung University (2012).